Aim To evaluate the adequacy and safety of current recommended dosage of Vitamin D (VitD) treatment in children diagnosed with vitamin D deficiency (vitDD) and role for routine follow-up VitD levels following treatment.
Method Retrospective audit of all children (0-16 years) diagnosed to have VitDD and received treatment, according to local guidelines, during 18 month period (Jan 2010-June 2011). Data on demographics, investigation, treatment and follow-up VitD levels were analysed. Dose of Cholecalciferol was that recommended in children's British National Formulary (cBNF).
Results 137 children fulfilled the criteria. 28% < 6 months age at diagnosis, 22% over 12 years and 50% within 6 m – 12 years age group. 80% (N=117) were South Asian (SA) ethnicity. There was equal distribution of cases throughout the year. 47% had no other underlying medical issues. 44% (N=60) were asymptomatic. 34 infants <6 months age were asymptomatic and diagnosed to have VitDD during prolonged jaundice screening. Bone pain was the most frequent presenting symptom amongst those symptomatic. 53% were severe deficient (VitD < 15 nmol/l), 32% deficient (15-30 nmol/l) and 15% insufficient (30-50 nmol/l). There was no significant difference in the severity of deficiency between asymptomatic and symptomatic groups. All received treatment for 8 weeks duration except 9% for 6 weeks (all had insufficiency rather than deficiency). 83% (N = 84) had followup VitD levels after treatment. 93% achieved levels within ‘ideal’ range (50-150 nmol/l) whilst 7% failed to achieve (compliance issue identified in all). 6 of the 20 children under 6 months age had followup level above the ideal range up to 200 nmol/l but not toxic level (> 500 nmol/l).
Conclusions VitDD is very common in children of SA ethnicity. Children with severe VitDD can be asymptomatic. Dose of Cholecalciferol recommended in cBNF for a period of 8 weeks to correct VitDD is safe to use except those under 6 months where a 6 week course is adequate. Routine followup VitD levels after treatment is not necessary unless compliance with treatment is considered and in those children <6 months age until further evidence of safety in this age group.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.